Deciphera Pharmaceuticals competitors

Troy Wilson is a highly-successful, serial entrepreneur. His passion is to build exceptional companies that create significant value for employees, investors and most importantly, patients. In addition to his role as President and CEO of Avidity NanoMedicines, Troy Wilson is President and CEO of Wellspring Biosciences as well as its affiliated company, Araxes Pharma. He also serves as a director of Puma Biotechnology, a biopharmaceutical company dedicated to the acquisition and development of novel therapeutics for the treatment of cancer. Troy Wilson previously served as President and CEO of Intellikine, a company which he co-founded and which was acquired by Takeda Pharmaceuticals in January 2012 for up to $310 million, and prior to Intellikine he was involved with the formation, launch and growth of several other companies. Troy Wilson received his Ph.D. degree in bioorganic chemistry from the University of California, Berkeley and his law degree from New York University.

Dr. Peltz founded PTC Therapeutics in 1998 and has served as Chief Executive Officer and a member of the board of directors since the company’s inception. Under his leadership, PTC has grown from a research organization to a publicly traded, global commercial organization with multiple approved products and a foundation of strong technology platforms that continues to drive a robust discovery pipeline for patients with rare disorders. Prior to founding PTC, Dr. Peltz was a Professor in the Department of Molecular Genetics & Microbiology at the Robert Wood Johnson Medical School, Rutgers University. Dr. Peltz is a recognized scientific leader in RNA biology in the area of post-transcriptional control processes involving mRNA turnover and translation, with more than 30 years of research and over 100 publications in this area. Dr. Peltz has received a number of business and scientific awards. Notably, he was elected as a Fellow of the American Academy for the Advancement of Science in 2010. He was recognized as PharmaVoice’s 100 Most Inspiring People in 2009 and received the Dr. Sol J. Barer Award for Vision Innovation and Leadership in 2014. Dr. Peltz received a Ph.D. from the McArdle Laboratory for Cancer Research at the University of Wisconsin.

Global leader in the oncology pharmaceutical sector having successfully developed, acquired and launched several multi-billion dollar oncology brands across multiple tumor types and therapeutic approaches. Over 3 decades of experience in US and International pharmaceutical development, product strategy, commercialization and business development; and, has cultivated an extensive network with specialists and companies developing new treatment approaches for patients living with cancer. Recently, founded Proventus Health Solutions, a company specializing in helping oncology biotech companies create greater value by integrating development and commercial considerations into a unified approach. A member of the board of directors for Verastem Oncology (VSTM) and Oncopeptides AB (ONCO).

J have worked as Chairman/Pres/CEO/Secy/Co-Founder at Genprex Inc. They work or have worked as MEMBER at STATE BAR OF TEXAS. J attended TAMU and University of Texas School of Law.

Armin Spura is a Chief Executive Officer at Crown bioscience.

John Gill works at Tetralogic Pharmaceuticals and a CEO at Tetralogic Pharmaceuticals and is based in Devon, Pennsylvania. He has worked as Director and Chief Operating Officer at 3-DIMENSIONAL PHARMACEUTICALS, INC.. John attended Rutgers University—Camden between 1973 and 1975 and Transylvania University between 1969 and 1971.